NCT03055234撤回3 期
A Phase 3, Multicenter, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Sickle Cell Disease
United Therapeutics0 个研究点开始时间: 2017年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 主要终点
- Effect of oral treprostinil compared with placebo on time to first adjudicated PH clinical worsening (morbidity or mortality) event in subjects with PH associated with SCD
研究概览
简要总结
This is a multicenter, randomized (2:1; oral treprostinil:placebo), double-blind, placebo-controlled event-driven (time to pulmonary hypertension [PH] clinical worsening) study in subjects with PH associated with sickle cell disease (SCD). Once enrolled, subjects will be evaluated at Weeks 6, 12, 24, and then every 12 weeks for the duration of the study. Subjects will be permitted to enter a 48-week open-label extension period if they experience a PH clinical worsening event.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject must have a diagnosis of SCD confirmed by hemoglobin electrophoresis.
- •The subject has a diagnosis of symptomatic World Health Organization (WHO) Group 5.1 chronic hemolytic anemia PH.
- •The subject must have a Baseline 6MWD greater than 150 meters, in the absence of a concurrent injury, illness, or other confounding factor.
- •The subject has pulmonary function tests conducted within 6 months of Screening or during the Screening period.
- •The subject must be on stable doses of other medical therapy for at least 30 days prior to randomization with no dose adjustments, additions, or discontinuations.
- •The subject must be optimally treated with conventional PH therapy for at least 10 days prior to randomization with no additions, discontinuations, or dose changes.
- •Subjects receiving an endothelin receptor antagonist (ERA) must have been receiving therapy for greater than 90 days, and have reached and maintained a stable dose for a minimum of 30 days prior to randomization.
- •Subjects receiving calcium channel blockers must have been on a stable dose for a minimum of 3 months prior to randomization.
排除标准
- •The subject is pregnant or lactating.
- •The subject has previously received oral treprostinil or is receiving a phosphodiesterase type 5 inhibitor (PDE5-I).
- •The subject has received a prostacyclin within 30 days prior to start of the study, or had previous intolerance or significant lack of efficacy to any prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to titrate that therapy effectively.
- •The subject has had any other background conventional therapies for PH added, removed, or doses adjusted within 10 days prior to randomization.
- •The subject has any disease associated with pulmonary arterial hypertension (PAH).
- •The subject has had a vaso-occlusive crisis, acute chest syndrome event, or unscheduled transfusion within 30 days of randomization.
- •The subject has a history of ischemic heart disease, including a previous myocardial infarction or symptomatic coronary artery disease, within 6 months prior to Screening or a left ventricular ejection fraction less than 40% assessed by either multigated angiogram (MUGA), angiography, or echocardiogram.
- •The subject has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels 3 times or greater than the upper limit of normal, clinically significant liver disease/dysfunction, or known Child-Pugh Class B or C hepatic disease at Screening.
- •The subject has chronic renal insufficiency, as defined by the requirement for dialysis.
- •The subject has a musculoskeletal disorder, any disease that is likely to limit ambulation, or is connected to a machine that is not portable.
- •The subject has an unstable psychiatric condition or is mentally incapable of understanding the objectives, nature, or consequences of the study, or has any condition which in the Investigator's opinion would constitute an unacceptable risk to the subject's safety.
- •The subject is receiving an investigational drug, has an investigational device in place, or has participated in an investigational drug or device study within 30 days prior to Screening.
研究组 & 干预措施
Oral Treprostinil
Experimental
Extended-release oral tablet for three times daily (TID) administration
干预措施: Oral Treprostinil (Drug)
Placebo
Placebo Comparator
Placebo (sugar pill) for TID administration
干预措施: Placebo (Drug)
结局指标
主要结局
Effect of oral treprostinil compared with placebo on time to first adjudicated PH clinical worsening (morbidity or mortality) event in subjects with PH associated with SCD
时间窗: Baseline until the first adjudicated PH clinical worsening event, assessed up to approximately 4 years
Clinical worsening is defined as the occurrence of any 1 of the following events: hospitalization related to PH and/or right heart failure, initiation of an infused prostacyclin to treat worsening PH, decrease in 6-Minute Walk Distance (6MWD) \>15% from Baseline directly related to disease under study.
次要结局
- Effect of oral treprostinil compared with placebo on exercise capacity as assessed by 6-Minute Walk Distance (6MWD)(Baseline to Week 24)
- Effect of oral treprostinil compared with placebo on combined 6MWD/Borg dyspnea score(Baseline to Week 24)
- Effect of oral treprostinil compared with placebo on Borg dyspnea score(Baseline to Week 24)
- Effect of oral treprostinil compared with placebo on maximal tricuspid regurgitant velocity (TRV) assessed by transthoracic Doppler echocardiography(Baseline to Week 24)
- Effect of oral treprostinil compared with placebo on N-Terminal pro-brain natriuretic peptide (NT-proBNP) levels(Baseline to Week 24)
研究者
相似试验
撤回
3 期
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT02999906United Therapeutics
终止
3 期
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionHeart Failure With Preserved Ejection FractionPulmonary HypertensionNCT03037580United Therapeutics84
已完成
3 期
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisDermatomyositisNCT05437263Priovant Therapeutics, Inc.241
已完成
3 期
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary AngioedemaNCT06343779Pharvaris Netherlands B.V.134
已完成
3 期
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the ScalpPsoriasisNCT03123471Amgen303